Johnson & Johnson's $5.5 billion talc settlement ends 15-year cancer litigation
Synopsis
After 15 years and thousands of lawsuits, Johnson & Johnson has put a $5.5 billion price tag on its talc litigation — but only if 95% of remaining claimants agree. A pivotal MDL court ruling on causation shifted the balance, and J&J is betting that most plaintiffs will take the deal rather than fight on weakened legal ground.
Key Takeaways
Johnson & Johnson has agreed to pay up to $5.5 billion to resolve remaining US talc-ovarian cancer lawsuits.
The deal requires at least 95 per cent of remaining claimants to participate before it takes effect.
First payment of up to $3 billion is scheduled for 2027 ; no further payments before 2028 .
A federal MDL court ruling found plaintiffs could not prove specific causation, strengthening J&J's negotiating position.
J&J discontinued talc-based JOHNSON'S Baby Powder globally in 2023 and spun off consumer unit Kenvue the same year, retaining all talc liabilities.
The settlement complements earlier deals covering roughly 95 per cent of mesothelioma and state consumer protection claims.
Johnson & Johnson (J&J) has agreed to pay up to $5.5 billion to resolve the remaining US lawsuits alleging its talc-based products caused ovarian cancer, the company announced on 28 July. The proposed settlement, which covers litigation pending in both federal and state courts, is contingent on at least 95 per cent of remaining claimants joining the agreement — bringing a close to one of the longest-running product liability battles in American corporate history.
Key Terms of the Settlement
Under the proposed resolution, J&J has committed the full $5.5 billion in phased payments. The first tranche — up to $3 billion — is scheduled for 2027, with no additional payments due before 2028. The deal will only become effective once the stipulated claimant participation threshold is met and all agreed conditions are fulfilled.
The settlement follows a significant ruling by the federal Multi-District Litigation (MDL) court, which found that plaintiffs were unable to prove specific causation — that is, that J&J's talc products directly caused any individual claimant's ovarian cancer. That ruling is widely seen as having shifted the legal landscape in J&J's favour ahead of the settlement.
What J&J Said
Erik Haas, Worldwide Vice President of Litigation at Johnson & Johnson, said the company remained confident the claims lacked scientific merit but opted to settle in order to bring the protracted litigation to a definitive close. J&J maintained that decades of research, clinical evidence, and assessments by independent experts support the safety of cosmetic talc, and that its talc products neither contain asbestos nor cause cancer.
Earlier Settlements and Business Changes
This agreement complements J&J's earlier settlements, which already covered approximately 95 per cent of filed mesothelioma lawsuits, state consumer protection claims, and disputes involving talc suppliers. Taken together, the two settlement tracks represent a near-comprehensive resolution of J&J's talc liability exposure.
Notably, J&J discontinued the global sale of talc-based JOHNSON'S Baby Powder in 2023 as part of a broader portfolio review. That same year, the company separated its consumer health division, Kenvue, into an independent entity — while retaining full responsibility for all talc-related liabilities, a structuring decision that drew scrutiny from plaintiff attorneys at the time.
What Happens Next
The settlement remains conditional. If the 95 per cent participation threshold among lead plaintiff firms is not met, the agreement does not automatically take effect. Legal observers will watch closely whether holdout claimants — who may believe their individual cases carry stronger causation evidence — choose to join or stay out. The outcome of that calculus will determine whether J&J achieves the clean legal slate it has sought for over a decade.
Point of View
Rather than fighting thousands of individual trials, is rational corporate risk management. What the headline number obscures is that J&J has consistently denied liability throughout, meaning this payout buys closure without admission. The more consequential question is whether the 95% participation threshold will hold — a single organised bloc of holdouts could unravel the deal and force J&J back into court on terms that may yet shift again.
NationPress
28 Jul 2026
Frequently Asked Questions
What is the Johnson & Johnson talc settlement?
Johnson & Johnson has agreed to pay up to $5.5 billion to resolve remaining US lawsuits alleging its talc-based products caused ovarian cancer. The settlement covers litigation in both federal and state courts and is contingent on at least 95 per cent of remaining claimants agreeing to participate.
Why did J&J agree to settle despite denying wrongdoing?
J&J stated it remained confident the claims lacked scientific merit but chose to settle to bring the long-running litigation to a close. A federal MDL court ruling that plaintiffs could not prove specific causation also shifted the legal landscape in the company's favour ahead of the deal.
When will J&J make the settlement payments?
The first payment of up to $3 billion is scheduled for 2027, with no additional payments due before 2028. The settlement only becomes effective once the 95 per cent claimant participation condition and other agreed terms are fulfilled.
What happened to J&J's talc products and consumer business?
Johnson & Johnson discontinued the global sale of talc-based JOHNSON'S Baby Powder in 2023 as part of a portfolio review. It also spun off its consumer health division as Kenvue in 2023, while retaining full responsibility for all talc-related liabilities.
How does this settlement relate to J&J's earlier talc deals?
This agreement complements earlier settlements that already covered approximately 95 per cent of filed mesothelioma lawsuits, state consumer protection claims, and disputes with talc suppliers. Together, the two tracks represent a near-complete resolution of J&J's talc legal exposure in the US.
